Dexamethasone Drug Implant [Ozurdex]
National Institutes of Health
Papers overview
Semantic Scholar uses AI to extract papers important to this topic.
Aims: To evaluate treatment outcomes of pro re nata dosing of intravitreal dexamethasone implant in eyes with refractory diabetic…
Objective: To analyse the cost-effectiveness and benefits of a dexamethasone intravitreal implant (Ozurdex®, Allergan, Irvine, CA…
Background: To evaluate the effect of Ozurdex® on intraocular pressure in patients with macular edema alone (group 1) or…
Purpose: To investigate the percentage and time of intraocular pressure (IOP) elevation and the factors influencing IOP elevation…
Purpose To evaluate the long‐term efficacy and safety of intravitreal implant of 0,7mg dexamathasone (ozurdex®) in diabetic…
ZusammenfassungHintergrundSeit Juli 2010 ist Ozurdex® in Deutschland für die Behandlung des Makulaödems (MÖ) von venösen…
BACKGROUND
The efficacy of a single dose of Ozurdex® was evaluated over a 6-month period in eyes with macular edema due to…
Purpose To report our experience with sustained-release dexamethasone 0.7 mg intravitreal implant (Ozurdex®; Allergan, Inc…